Position of Ocular Therapeutix Inc (OCUL) stimulated by The Manufacturers Life Insurance Company

Business



[ad_1]

Ocular Therapeutix logo "title =" Ocular Therapeutix logo "class =" companylogo "/> The Manufacturers Life Insurance Company increased its holdings in Ocular Therapeutix Inc (NASDAQ: OCUL) by 328.4% at 1st quarter, according to its latest filing with the Securities and Exchange Commission (SEC) by the 13F The company held 24,123 shares of the biopharmaceutical company after purchasing 18,492 additional shares during the quarter the Insurance Company- Life Manufacturers held approximately 0.06% of Ocular Therapeutix worth $ 157,000 </p> <p> Several other institutional investors and hedge funds also bought and sold shares of BlackRock Inc. increased its holdings of Ocular Therapeutix shares of 0.8% in the fourth quarter, 1,418,577 shares of the biopharmaceutical company worth $ 6,312,000 after acquiring an additional 11,293 shares in the last 1st quarter of Ocular Therapeutix of 148.7% in the fourth quarter. Deutsche Bank AG now holds 50,065 shares of the biopharmaceutical company valued at $ 221,000 after the purchase of 29,938 additional shares during the period. Schwab Charles Investment Management Inc. increased its position in Ocular Therapeutix shares by 39.3% in the first quarter. Schwab Charles Investment Management Inc. now holds 53,570 shares of the biopharmaceutical company valued at $ 349,000 after purchasing 15,100 additional shares during the period. Summer Road LLC purchased a new equity stake in Ocular Therapeutix during the first quarter, valued at $ 19,709,000. Lastly, Northern Trust Corp increased its position in Ocular Therapeutix shares by 24.1% in the first quarter. Northern Trust Corp. now holds 324,526 shares of the biopharmaceutical company valued at $ 2,112,000 after purchasing 62,993 additional shares during the period. 57.76% of the shares are held by institutional investors and hedge funds. </p> <p> A number of equity research analysts have published reports on the company. Cantor Fitzgerald set a price target of $ 22.00 on Ocular Therapeutix and awarded the company a "buy" rating in a research report on Tuesday, May 8th. ValuEngine has elevated Ocular Therapeutix from a "strong sale" rating to a "sell" note in a research report on Tuesday, July 10. Zacks Investment Research downgraded Ocular Therapeutix from a "buy" rating to a "sell" rating in a research report on Saturday, May 12. HC Wainwright confirmed a "buy" note and issued a target price of $ 10.00 on Ocular Therapeutix shares in a research report on Thursday, June 21st. Finally, BidaskClub changed Ocular Therapeutix from a "hold" note to a "buy" note in a research note on Friday, June 15th. Two research analysts rated the title with a sales note, one assigned a holdback rating and four issued a buy-to-action note. Ocular Therapeutix currently has an average rating of "Hold" and an average price target of $ 12.81. </p> <p> Ocular Therapeutix fell $ 0.23, reaching $ 5.50 on Friday, according to MarketBeat.com. 305,718 shares were exchanged for an average volume of 416,714. Ocular Therapeutix Inc. has a twelve-month low of $ 3.30 and a twelve-month high of $ 8.28. The stock has a market capitalization of $ 214.73 million, a price / earnings ratio of -2.50 and a beta of 1.27. The company has a quick ratio of 4.89, a ratio of 4.90 and a debt ratio of 0.22. </p> <p> Ocular Therapeutix (NASDAQ: OCUL) last announced its quarterly results on Tuesday, May 8th. The biopharmaceutical company reported ($ 0.40) earnings per share (EPS) for the quarter, with the exception of Thomson Reuters' consensus estimate of ($ 0.38) of (0.02 $). Ocular Therapeutix posted a negative net margin of 3,418.79% and a negative return on equity of 153.53%. The company achieved a turnover of $ 0.34 million for the quarter. Analysts predict that Ocular Therapeutix Inc. will display -1.55 EPS for the current year. </p> <p> <strong> About Ocular Therapeutix </strong> </p> <p> Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for eye diseases and conditions in Canada. using its bioabsorbable hydrogel platform. Its main product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical eye pain and inflammation, allergic conjunctivitis and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. </p> <p> Feature article: What kind of dividend relates to CEF's remuneration? <br /><!--ViewCount:type=f&id=3634395--></p> <p style= Institutional holdings by quarter for Ocular Therapeutix (NASDAQ: OCUL)

Receive news and ratings for Ocular Therapeutix Daily – Enter your email address below to receive a daily concise summary of the latest news and notes from Analysts for Ocular Therapeutix and related companies with the free daily electronic newsletter of MarketBeat.com.

[ad_2]
Source link

Tags

Powered by https://naaju.com/philippines | Designed by Naaju
© Copyright 2025, All Rights Reserved